HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $350 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $350 price target.
Follow the latest Revolution Medicines, Inc. (RVMD) news and market headlines alongside the live RVMD price. Stay informed on what's moving RVMD.

HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $350 price target.
The European Commission has approved RASONQUE (daraxonrasib) by Revolution Medicines for treating adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. The approval, based on positive Phase 3 RASolute 302 trial results, represents a significant advancement for pancreatic cancer treatment in the EU, with the company working to enable patient access through national pricing and reimbursement processes.
Morgan Stanley analyst Sean Laaman maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and lowers the price target from $272 to $247.
The FDA reportedly shelves its fast-track drug voucher pilot amid internal chaos, returning review oversight to career scientists.
Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 30.9% on an annualized basis producing an average annual return of 41.09%. Currently, Revolution Medicines has a market
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to RVMD, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.